IGA (Investigator Global Assessment) scores are numerical ratings that dermatologists use to measure acne severity during clinical trials. On a scale of 0 to 4, where 0 means completely clear skin and 4 indicates severe acne, these scores determine whether a new acne treatment actually works well enough for FDA approval. In practical terms, if a trial participant starts with a score of 3 (moderate acne) and ends with a score of 1 (almost clear), that improvement helps prove the treatment is effective.
Understanding IGA scores matters whether you’re evaluating a new acne medication, participating in a clinical trial, or simply wanting to know how dermatologists objectively measure acne severity in research settings. This article explains how the IGA scale works, why the FDA made it the standard for acne drug trials, what success actually looks like in these studies, and how artificial intelligence is beginning to change the way these assessments are conducted. You’ll learn what dermatologists are actually looking for when they assign these scores, why the baseline measurement is so important, and how the results of trials using IGA scoring directly influence which acne treatments make it to market.
Table of Contents
- How the IGA Scale Works and What Each Score Means
- What FDA Considers a “Success” in Acne Trials
- The Role of the Dermatologist in Assessing IGA Scores
- Understanding Improvement and What It Means for Treatment Outcomes
- The Rise of Artificial Intelligence in IGA Scoring
- How IGA Scores Influence Real-World Treatment Decisions
- The Future of Acne Assessment in Clinical Trials
- Conclusion
- Frequently Asked Questions
How the IGA Scale Works and What Each Score Means
The Investigator global Assessment scale uses five simple grades to classify acne severity: 0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), and 4 (severe). A dermatologist assigns a single score to each patient during a trial visit by looking at the face as a whole and making a judgment call about overall acne burden. This isn’t about counting individual pimples—it’s a holistic assessment that considers the total extent of inflammation, the distribution of lesions across the face, and how significantly the acne is affecting the skin’s appearance. The score is determined during a static evaluation, meaning it’s based on a single observation at a specific point in time, typically during an office visit or clinic appointment.
Since its FDA approval in 2005, the IGA scale has become the standard severity measure used across virtually all acne clinical trials. A dermatologist conducting the assessment looks for overall facial acne severity, considering all lesions and inflammation present on the day of evaluation. This approach provides consistency across different studies and allows researchers to compare results meaningfully. However, it’s important to note that IGA scoring relies on the expertise and judgment of the evaluating physician, so training and standardization of assessors is critical in maintaining quality across multi-site trials.
What FDA Considers a “Success” in Acne Trials
The FDA doesn’t just want to see any improvement in acne. The regulatory threshold for approving a new acne drug requires two specific criteria to be met: the patient must achieve at least a 2-grade improvement from their baseline IGA score, and their final score must be either 0 (clear) or 1 (almost clear). This means that if someone started a trial with a score of 4 (severe acne), simply reaching a score of 3 (moderate) wouldn’t qualify as success—they would need to reach at least a score of 2, and then continue to improve further to reach 0 or 1. These rigid endpoints exist because the FDA wants objective evidence that treatments genuinely clear acne rather than just making it slightly better.
This two-part success definition ensures that new acne medications don’t receive approval based on modest improvements that might not be noticeable to patients or clinically meaningful. Participants who end a trial with moderate acne remaining, even if they’ve improved from severe, don’t count as successes in the regulatory sense. The requirement also protects patients from ineffective or marginally effective treatments entering the market. However, a limitation of this approach is that baseline enrollment criteria must ensure patients are stratified appropriately—the FDA mandates that baseline IGA scores align with baseline lesion counts, so researchers can’t enroll people with wildly inconsistent severity measurements.
The Role of the Dermatologist in Assessing IGA Scores
During a clinical trial, a trained dermatologist or qualified healthcare professional is responsible for conducting the IGA evaluation. The assessment is visual and happens during a single appointment, with the evaluator looking at the patient’s face to determine overall severity. The professional isn’t pulling out a checklist to count comedones or measure pimple diameter; instead, they’re applying clinical judgment shaped by years of training to classify the overall picture of acne they’re seeing. A patient with inflammatory papules scattered across both cheeks, forehead, and chin with significant redness might receive a 3 (moderate), while someone with only a few small lesions in one area might score 1 (almost clear).
Consistency in these assessments is maintained through evaluator training and standardization procedures before the trial begins. Multiple sites participating in a multi-center trial might use the same dermatologist or dermatologists trained to assess IGA the same way. In larger studies, researchers sometimes conduct consistency checks by having two evaluators score the same patient to ensure agreement. The subjective nature of this assessment—relying on professional judgment rather than an automated measurement—is actually a strength when done properly, because a skilled dermatologist can integrate information about inflammation, lesion type, and overall disease burden in ways that a simple lesion count might miss.
Understanding Improvement and What It Means for Treatment Outcomes
When you see results from an acne drug trial, the IGA improvement is the headline metric. If a press release states that 60% of patients achieved a 2-grade or greater improvement with a final score of 0 or 1, that means the treatment met FDA’s success criteria in six out of ten participants. Compare this to a placebo group where perhaps 25% of patients achieved the same improvement—the difference suggests the medication is genuinely effective beyond what you’d expect from the passage of time or placebo effect. A patient who starts with a baseline IGA of 4 and reaches 0 has achieved a remarkable outcome and is included in those success percentages.
However, the baseline IGA score matters enormously for interpreting results. A trial enrolling only patients with baseline IGA of 3 or 4 (moderate to severe acne) will naturally show larger numeric improvements than a trial that includes patients with baseline IGA of 2 (mild). Two trials showing the same percentage of patients achieving success might have very different patient populations and severity profiles. The regulatory requirement that baseline IGA be consistent with lesion counts helps prevent researchers from stacking trials with the mildest possible patients, which would artificially inflate success rates. Understanding the baseline distribution in a trial helps you interpret whether the treatment works for acne severity level similar to your own.
The Rise of Artificial Intelligence in IGA Scoring
As of 2024 and 2025, artificial intelligence algorithms have been developed to automate IGA scoring directly from photographs of the face. This technology could potentially reduce evaluator bias and make trial assessments more efficient. An AI model is trained on thousands of photographs that dermatologists have already scored, learning to recognize the visual patterns associated with each IGA grade. In theory, an algorithm could then score new photographs consistently without the variability that might occur if different dermatologists were assessing patients at different sites.
Despite the promise, current AI methods for IGA scoring are not yet ready to replace dermatologists in clinical trials. Recent research shows that artificial intelligence algorithms achieve approximately 67% classification accuracy when analyzing frontal facial images to predict IGA scores. That means roughly one-third of the time, the AI system assigns a different score than a dermatologist would. For a clinical trial where accuracy is critical to getting accurate results, a 67% accuracy rate is too low to serve as the primary assessment method. However, AI could potentially assist dermatologists by flagging borderline cases or providing a second opinion, which might improve consistency in multi-site trials over time as the algorithms continue to improve.
How IGA Scores Influence Real-World Treatment Decisions
Beyond their role in FDA drug approval, IGA scores provide clinicians and patients with a common language for discussing acne severity. When your dermatologist notes that your acne is moderate (IGA 3) rather than mild (IGA 2), that assessment helps guide treatment recommendations. Someone with mild acne might respond to topical treatments alone, while moderate or severe acne often requires systemic medications like oral antibiotics or isotretinoin.
The IGA score gives you a standardized way to track your own improvement over months of treatment, similar to how a baseline score in a clinical trial marks your starting point. Because the IGA scale was developed and refined specifically for clinical trial settings, it’s worth noting that your dermatologist’s informal assessment of your acne might differ slightly from how an official IGA scorer would evaluate you. In routine clinical practice, dermatologists use judgment and experience rather than the rigid standardization required in trials. Nevertheless, when your dermatologist describes improvement over time, they’re often using concepts aligned with the IGA scale—for example, noting that your acne has gone from moderate to mild with fewer inflammatory lesions visible.
The Future of Acne Assessment in Clinical Trials
The acne treatment landscape continues to evolve with new medications, delivery systems, and combination therapies in development. As trials become more sophisticated and international, maintaining standardized severity assessment across different healthcare systems and cultures will remain important. Ongoing refinements to AI algorithms and the possibility of hybrid approaches—where dermatologists use AI assistance to improve consistency—may eventually transform how IGA scoring works in future trials without abandoning the clinical judgment that dermatologists bring.
The IGA scale has remained the gold standard for nearly two decades, which speaks to its reliability and clinical relevance. Whether AI ultimately plays a larger role in acne assessment or dermatologists continue to evaluate patients directly, the 0-to-4 IGA framework will likely persist as a key measure of how well new acne treatments truly work. For patients interested in emerging acne therapies, understanding what these trial scores mean helps you evaluate the strength of evidence behind a new treatment option.
Conclusion
IGA scores represent the FDA’s attempt to create an objective, standardized way to measure whether acne treatments actually work. The 5-point scale from clear (0) to severe (4) has been the benchmark for acne clinical trials since 2005, with FDA approval requiring at least a 2-grade improvement and a final score of 0 or 1. Dermatologists perform these assessments by visually evaluating overall facial acne severity, and the consistency of these professional judgments directly influences whether new medications reach patients.
As artificial intelligence technology develops and potentially assists with IGA scoring in future trials, the basic principles of what these scores measure will remain the same. If you’re considering a new acne treatment or evaluating trial results, the IGA scoring system provides reliable information about effectiveness. The next time you see a clinical trial result mentioning IGA improvement rates, you’ll understand that the numbers represent real patients achieving clearance of their acne based on a standardized assessment that dermatologists have used successfully for nearly two decades.
Frequently Asked Questions
Does a higher IGA score always mean worse acne?
Yes. On the 0-to-4 scale, higher numbers indicate more severe acne. A score of 4 represents severe acne, while 0 means completely clear skin.
Can I determine my own IGA score by looking in the mirror?
You shouldn’t try to self-assess using the IGA scale, as it requires the trained clinical judgment of a healthcare professional. What might look moderate to you could appear different to a dermatologist considering inflammation, distribution, and overall burden.
Why do acne trials require such a big improvement to count as “success”?
The FDA’s 2-grade improvement requirement ensures treatments genuinely work rather than produce marginal improvements that might occur naturally or from placebo. This protects patients by preventing ineffective medications from reaching the market.
If I’m on acne medication, should I ask my dermatologist to use the IGA scale to track my progress?
While your dermatologist uses clinical judgment in routine practice (which is informed by concepts like the IGA scale), most routine appointments won’t involve formal IGA scoring. That’s primarily a clinical trial tool. Your dermatologist will use their professional assessment of improvement, which serves the same purpose.
Is the IGA scale used for other skin conditions besides acne?
The IGA scale was specifically developed for acne trials. Other skin conditions typically have their own standardized severity scales designed for their unique characteristics.
Will AI completely replace dermatologists in assessing acne severity?
Current AI systems achieve only about 67% accuracy in IGA classification, so they’re not reliable enough to replace dermatologist assessment in trials. AI may eventually assist dermatologists in improving consistency, but clinical judgment remains essential.
